Delivery Order SPE2DB24D2100-SPE2DB25FBGMA
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) at a ceiling value of $1,118.30. This delivery order represents a firm fixed-price procurement with no set-aside designation, issued under a competitive process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (60 ml) with a ceiling value of $1,575.42. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with a contract value of $1,672.09 and completion deadline of September 26, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating the award resulted from open competition. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $1,202.39. This firm fixed price delivery order, which will be completed by October 30, 2025, represents a non-competitive, open-market award supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,357.46 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 150 mL quantity. The contract is structured as a firm fixed price delivery order with a completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating the contract was competitively procured through open competition. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,164.94 to supply Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on November 3, 2025, with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGMADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 180 mL quantity, with a ceiling value of $3,591.19. This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a non-set-aside competitive award. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The current award for Quillivant XR—a central nervous system stimulant medication commonly prescribed for attention deficit hyperactivity disorder—demonstrates the contractor's role in delivering essential pharmaceutical commodities to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 9/18/25 |